Want to join the conversation?
Pharma company $MYL announced the US launch of Dextroamphetamine Sulfate extended-release capsules for treatment of narcolepsy and attention deficit disorder with hyperactivity. $MYL received final approval from the US FDA for its ANDA for this product, which had US sales of approx. $101.3MM for the 12 months ending May 31, 2016.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.